Regulatory T (Treg) cells play a pivotal role in suppressing self-harmful T cell responses, but how Treg cells mediate suppression to maintain immune homeostasis and limit responses during inflammation is unclear. Here we show that effector Treg cells express high amounts of the integrin avb8, which enables them to activate latent transforming growth factor-b (TGF-b). Treg-cell-specific deletion of integrin avb8 did not result in a spontaneous inflammatory phenotype, suggesting that this pathway is not important in Treg-cell-mediated maintenance of immune homeostasis. However, Treg cells lacking expression of integrin avb8 were unable to suppress pathogenic T cell responses during active inflammation. Thus, our results identify a mechanism by which Treg cells suppress exuberant immune responses, highlighting a key role for effector Treg-cell-mediated activation of latent TGF-b in suppression of selfharmful T cell responses during active inflammation.
In Brief
Regulatory T (Treg) cells suppress harmful T cell responses, but mechanisms mediating suppressive function during homeostasis versus inflammation are poorly defined. Travis and colleagues show that activation of the cytokine TGF-b by effector Treg cells, via expression of integrin avb8, is crucial for Treg-cell-mediated suppression of inflammatory T cells. (Rudensky, 2011) . Mutations in Foxp3 cause severe T-cell-mediated multi-organ inflammation in both mice and humans, highlighting a critical role for Treg cells in maintaining T cell homeostasis. Additionally, the transfer of Treg cells into mouse models of inflammatory disease actively suppresses harmful T cells to prevent inflammation (Maloy and Powrie, 2011 ). There are current clinical trials using Treg cells that attempt to dampen T cell responses in several human inflammatory disorders (Tang and Bluestone, 2013) . Thus, it is paramount that the mechanisms by which Treg cells control immunity be determined, to identify pathways that can be targeted to promote Treg cell function. A crucial molecule that controls many aspects of Treg cell biology is the cytokine transforming growth factor-b (TGF-b). TGF-b plays a fundamental role in the development of Treg cells, both in the induction pTreg cells (Chen et al., 2003) and in the development of tTreg cells (Konkel et al., 2014; Liu et al., 2008) . In addition to roles in Treg cell development, TGF-b plays a fundamental role in the functional ability of Treg cells to suppress T cell responses. Although initial in vitro assays of Tregcell-mediated suppression both supported and contradicted a functional role for TGF-b (Dieckmann et al., 2001; Jonuleit et al., 2001; Marie et al., 2005; Nakamura et al., 2001; Oida et al., 2006; Takahashi et al., 1998; Thornton and Shevach, 1998) , there is now clear evidence that TGF-b plays a key role in mediating Treg cell suppressive function in vivo. Thus, T cells with a reduced capacity to respond to TGF-b cannot be suppressed by Treg cells in mouse models of colitis (Fahlé n et al., 2005; Liu et al., 2003) and experimental autoimmune encephalomyelitis (Zhang et al., 2006) , and production of TGFb1 by Treg cells is required for their suppression of colitic T cells in vivo (Nakamura et al., 2004; Pesu et al., 2008) . Although some studies have suggested that TGF-b1-deficient Treg cells are still capable of suppressing T-cell-mediated colitis (Fahlé n et al., 2005; Kullberg et al., 2005) , this suppression is completely abolished by an anti-TGF-b-blocking antibody (Fahlé n et al., 2005) , again highlighting the crucial role of TGF-b in Treg-cellmediated suppression in vivo. However, although TGF-b plays a crucial, non-redundant role in suppression of T cells by Treg cells in vivo, how TGF-b is regulated to mediate Treg cell suppressive function is poorly understood. TGF-b is always produced as an inactive precursor, which must be activated in order to bind its receptor and produce biological function (Worthington et al., 2011a) . The tgfb gene encodes latency-associated peptide (LAP) upstream of the active TGF-b moiety, which is cleaved from the active cytokine but remains non-covalently attached in a conformation that prevents TGF-b from engaging its receptor. Known activators of TGF-b include a variety of proteases and cell surface molecules that somehow alter the latent complex so that active TGF-b can engage its receptor (Worthington et al., 2011a) . Activation of the latent complex is therefore essential for regulation of TGF-b function, yet how TGF-b activation is regulated to control Treg cell suppressive function is completely unknown. Additionally, whether TGF-b plays an important role in Treg-cell-mediated suppression in all situations or whether this pathway is important in only certain immunological settings is a crucial but unanswered question.
Here we show that Foxp3 + Treg cells are specialized activators of TGF-b via expression of the integrin avb8 and that expression of the integrin is upregulated on activated/effector (e)Treg cells, indicating a potential role in Treg-cell-mediated modulation of active inflammation. Indeed, although lack of expression of integrin avb8 on Treg cells does not result in a break in Tregcell-mediated tolerance at rest, Treg cells lacking expression of the integrin are completely unable to suppress T-cell-mediated inflammation in vivo. These results therefore identify a mechanism by which activated/eTreg cells specifically control inflammatory T cells, highlighting a key role for Treg-cell-mediated activation of latent TGF-b in suppression of self-harmful T cell responses. (Abe et al., 1994) . Interestingly, Foxp3 + Treg cells showed an enhanced ability to activate latent TGF-b compared with both naive and effector/memory T cells ( Figure 1A ). To determine mechanisms by which Foxp3 + Treg cells are specialized to activate TGF-b, we examined Treg cells for molecules that could potentially activate the latent cytokine. We focused on the potential role of integrin avb8, which we have previously shown to be expressed by tolerogenic dendritic cells, enabling them to activate TGF-b, a pathway that is crucial in controlling immune homeostasis and responses to infection (Travis et al., 2007; Worthington et al., 2011b Worthington et al., , 2013 . We analyzed expression of the integrin b8 subunit (which pairs only with integrin av) at the RNA level, because there are no current antibodies available that recognize murine integrin b8. We found that Foxp3 + Treg cells expressed $100-fold higher levels of integrin b8 mRNA than naive and effector memory CD4 + T cells ( Figure 1B ). Expression of integrin av (which pairs with the additional subunits b1, b3, b5, and b6) was similar in all T cell subsets ( Figure S1A ). Using Treg cells isolated from mice expressing a conditional allele of integrin b8 (Itgb8) combined with Cd4-Cre (herein called Itgb8 KO Treg cells) (Travis et al., 2007) , we found that such cells no longer displayed the heightened activation of latent TGF-b compared to control Treg cells ( Figure 1C (Workman et al., 2011) . Both control and Treg cells lacking expression of integrin b8 were isolated to similar purities (>94% Foxp3 + ) before transfer (Figures S1B and S1C). We found that Itgb8 KO Treg cells showed a complete failure to suppress T cell expansion compared to the reduction seen with control Treg cells ( Figure 1D ). This lack of suppression was not due to any alterations in Treg cell establishment or loss of Foxp3 expression, as shown by the fact that equivalent percentages and Foxp3 expression was found in both transferred control and Itgb8 KO Treg cells ( Figure 1E ). In the presence of control Treg cells, we observed a specific increase in phosphorylation of Smad 2/3 (pSmad2/3) in CD4 + T cells ( Figure 1F ), which is the initial signaling event triggered by engagement of TGF-b with its receptor (Worthington et al., 2011a) . CD4 + T cell pSmad2/3 levels were lower in the presence of Itgb8 KO Treg cells, indicating that T cells were not seeing as much active TGF-b in the presence of integrin b8-deficient Treg cells (Figure 1F ). There was no difference in the amount of pSmad2/3 between the control and Itgb8 KO Treg cells, indicating that the difference in TGF-b signaling was specific to transferred T cells and not Treg cells at this time point ( Figure 1F (Rubtsov et al., 2008) . Despite
RESULTS

Treg Cell Expression of the TGF-b-Activating Integrin
Treg-cell-expressed integrin avb8 being essential for suppression of T cell expansion ( Figure 1D ), we found that Itgb8 fl/fl foxp3 YFP-Cre mice developed no spontaneous inflammatory phenotype. Thus, such mice display similar T cell development ( Figure 2A ) and T cell numbers in spleen and intestinal tissue (Figure 2B ) when compared to control mice. There were also similar Treg cell quantities in these compartments, although a slight increase in the splenic Treg cell population was observed (Figure 2C ), consistent with a previous report that mice lacking TGF-b signaling specifically on Foxp3 + Treg cells show slightly elevated Treg cell numbers (Gutcher et al., 2011) . Similar T cell activation and cytokine profiles were observed in intestinal tissue, with a slightly increased T cell activation and CD4 + IFN-g production observed in the splenic T cell population ( Figures  2D and 2E ). However, this slight increase in splenic T cell activation did not appear biologically significant; mice appeared healthy up until at least 12 months of age and showed no signs of colitis ( Figure 2F ) or immune pathology in organs examined ( Figure 2G ). These results indicate that TGF-b activation by Treg-cell-expressed integrin avb8 is not required for Treg-cellmediated control of T cell tolerance at rest. Figure S1 .
Integrin avb8 Is Preferentially Expressed on Activated Foxp3 + Treg Cells Given that integrin avb8 expression by Treg cells appeared essential for suppression of T cell expansion but redundant for Treg-cell-mediated maintenance of T cell homeostasis, we hypothesized that activation of latent TGF-b by Treg-cell-expressed integrin avb8 might play a role during inflammatory responses when both CD4 + T cells and Treg cells are activated. We first examined expression of integrin b8 on resting versus activated Treg cell subsets. We found that, whereas activation of naive CD4 + T cells did not alter expression of the integrin, activation of Treg cells with anti-CD3 and anti-CD28 antibodies increased expression of integrin b8 ( Figure 3A) , with integrin av expression remaining unaltered ( Figure S2A ). Furthermore, activated Treg cells had increased capacity to activate TGF-b, which was completely dependent on the expression of integrin avb8 by activated Treg cells ( Figure 3B ). We next determined whether integrin avb8 was preferentially expressed on activated Treg cell subsets in vivo. Indeed, we found highly elevated expression of integrin b8 mRNA by KLRG1 + Treg cells ( Figure 3C ), which are a subset of Treg cells proposed to represent a terminally differentiated activated/eTreg cell state (Feuerer et al., 2010) . The integrin av was also highly expressed on this KLRG1 + eTreg cell population ( Figure S2B ). Similar to in vitro activated Treg cells, KLRG1 + Treg cells showed significantly elevated ability to activate latent TGF-b versus KLRG1 À Treg cells, which was completely dependent on the expression of integrin avb8 ( Figure 3D ). Taken together, these data demonstrate that integrin avb8 is expressed primarily on activated Treg cells, especially on terminally differentiated eTreg cells.
Integrin avb8 Expression Is Essential for Treg Cell Suppressive Function during Inflammation
Given the elevated expression of integrin avb8 on eTreg versus non-eTreg cells, we hypothesized that integrin avb8 expression might play an essential role in preventing immunopathology during ongoing inflammation. To address this possibility, we utilized the T cell transfer model of colitis, which acts as an in vivo model for Treg cell suppression of inflammatory T cells (Powrie et al., 1994) . In this model, Rag2 À/À mice receive naive (CD4 + CD45RB hi CD25 À ) T cells, resulting in a wasting disease after 6-8 weeks, which can be reversed by transfer of Treg cells (Maloy et al., 2005) . Given that KLRG1 + Treg cells express significantly elevated levels of functional integrin avb8 ( Figures 3C and 3D ), we initially tested whether KLRG1 + Treg cell numbers are altered during inflammation. To this end, we examined Treg cell populations during homeostasis compared to Treg cells at 6 weeks after transfer into colitic mice. We found that, compared to Treg cells at rest, the percentage of KLRG1 + eTreg cells in the transferred population was significantly increased in splenic, mLN, and intestinal tissues ( Figure 4A ) and that these KLRG1 + Treg cells expressed high levels of integrin b8 mRNA ( Figure 4B ). Thus, these data indicate that exposure to an inflammatory environment causes an expansion of the KLRG1 + eTreg cell subset expressing high amounts of integrin b8.
To directly test the functional role for integrin avb8 expression by Treg cells in their ability to suppress inflammatory T cell responses, we tested the suppressive ability of Treg cells lacking expression of integrin b8 in the transfer colitis model. When Treg cells were transferred at a time when inflammation was not yet present (i.e., at the same time as naive T cells), both control and Itgb8 KO Treg cells completely suppressed weight loss and the development of colitis ( Figures S3A-S3D ), in agreement with recent findings (Edwards et al., 2014) and the findings that integrin b8 expression on Treg cells does not play a function in preventing inflammation during homeostasis (Figure 2) . However, when Treg cells were transferred 2 weeks after naive CD4 + T cell transfer into an inflammatory environment, Itgb8 KO Treg cells completely failed to rescue disease, with weight loss and histological scores being indistinguishable from mice not receiving Treg cells ( Figures 4C and 4D ). This lack of suppression was in contrast to control Treg cells, which completely suppressed weight loss and inflammation (Figures 4C, 4D, S3E, and S3F) .
Previous work has demonstrated that Treg cells suppress both the innate and adaptive arms of the immune response during T-cell-induced colitis (Maloy et al., 2003 and Itgb8 WT/fl foxp3 YFP-Cre control mice), with enhanced ear thickness ( Figure 5D ) and inflammation ( Figure 5E ) and enhanced numbers of CD4 + and CD8 + T cells producing IFN-g ( Figure 5F ). Thus, taken together, these results show that, despite the ability of Treg cells lacking expression of integrin avb8 to maintain T cell homeostasis and prevent initial development of inflammation in vivo, expression of this integrin is required for the capacity of Treg cells to suppress effector T cells during inflammation. Figure 7A ).
Lack of Integrin
Total human Foxp3 + Treg cells also expressed enhanced amounts of the integrin av subunit ( Figure S5A ). We next sought to determine whether expression of integrin avb8 was enriched on eTreg cells in humans, similar to our observations in mice (Figure 2) . To this end, we isolated Treg cells from the following populations from healthy human blood: the fraction (Fr.) II population (CD45RA À and CD25 hi ) expressing the highest amounts of Foxp3, activation, and suppressive capacity (Miyara et al., 2009) (Afzali et al., 2013) . All of these Treg cell subsets express the integrin av subunit ( Figure S5B ). However, comparable to our data in mice showing highest expression of integrin b8 mRNA on activated/eTreg cells, we found that the human Fr. II effector Treg cell population expresses the highest amounts of integrin b8 (Figure 7B) . The intermediately suppressive Fr. III Treg cell population See also Figure S4 and Tables S1 and S2. also expresses integrin b8, albeit at lower levels than the more suppressive Fr. II population, whereas the resting Fr. I Treg cell population does not express detectable levels of integrin b8 (Figure 7B) . Taken together, these data suggest that, similar to observations in mice, human eTreg cell populations express integrin avb8 and this expression directly correlates with their ability to suppress T cell responses (Miyara et al., 2009 ).
DISCUSSION
Despite strong evidence indicating that TGF-b plays a nonredundant role in Treg-cell-mediated suppression of T cells in vivo, the mechanisms by which TGF-b is regulated during Treg-cell-mediated suppression are completely unknown. We now demonstrate that Treg cells are specialized to activate latent TGF-b due to expression of the TGF-b-activating integrin avb8, with activated/eTreg cells showing highly upregulated expression of the integrin in both mice and humans. Although expression of integrin avb8 on Treg cells is not required to maintain T cell tolerance or prevent T-cell-mediated inflammation, it is essential to suppress T cell responses during ongoing inflammation. These results therefore identify a novel mechanism by which activated Treg cells specifically control inflammatory T cells, highlighting a key role for Treg-cell-mediated activation of latent TGF-b in suppression of harmful T cell responses. Exactly how integrin avb8 mediates activation of TGF-b by Treg cells is not clear. Integrin avb8 binds to an RGD motif present in LAP, and activation of TGF-b by integrin avb8 has been proposed to involve the membrane metalloprotease MMP14 in airway cells (Mu et al., 2002) , which cleaves LAP to release active TGF-b. However, we find no evidence for increased expression of MMP14 in either naive Treg cells or eTreg cell subsets compared to naive T cells (data not shown), and therefore the role for MMP14 in promoting enhanced integrin avb8-mediated TGF-b activation in Treg cells is unclear. Additionally, whether integrin avb8 expression in a T cell is sufficient to convey a regulatory phenotype is unknown, although it is likely that additional factors synergize with the integrin b8-TGF-b pathway to mediate Treg cell suppression during inflammation.
Lack of integrin avb8 expression on Treg cells completely abrogated their ability to suppress T cell responses during inflammation, so it was important to determine the mechanism by which Treg cell expression of integrin avb8 controlled inflammatory T cells. Treg cells can convert naive T cells into pTreg cells Edwards et al., 2013) . Therefore, one possibility for the failure of Itgb8 KO Treg cells to suppress inflammation was a failure to convert colitic T cells into pTreg cells, thus lacking so-called ''infectious tolerance.'' Similarly, lack of integrin avb8-mediated TGF-b activation could lead to reduced stability of Treg cells, given that TGF-b plays an important role in maintenance of Foxp3 expression (Marie et al., 2005) and the ability of Treg cells that lose Foxp3 expression to become pro-inflammatory ''ex-Treg cells'' during inflammation (Komatsu et al., 2014; Zhou et al., 2009 ). However, we observed equivalent percentages of pTreg cells induced in the transferred T cell population in colitis models, and also equivalent percentages of transferred control and Itgb8 KO Treg cells expressing similar levels of Foxp3, strongly indicating that induction of pTreg cells and stability of transferred Treg cells is not dependent on ) and integrin b8 expression measured by qPCR. b8 mRNA were normalized to the housekeeping gene B2M and presented relative to naive T cell levels (naive, n = 8; effector/memory, n = 7; Treg cell, n = 4). expression of integrin avb8. These findings fit with previous observations in vitro, which suggest that infectious tolerance is independent of the actions of av integrins (Kullberg et al., 2005) are still able to suppress T-cell-mediated colitis, in contrast to the inability of T cells that cannot sense TGF-b to be suppressed by Treg cells (Fahlé n et al., 2005) . Thus, taken together with previous studies, our data support a model in which TGF-b, activated by integrin avb8 expressed by Treg cells, acts in a paracrine fashion upon CD4 + T cells to suppress inflammation. An important outstanding question is which cells produce the functionally important TGF-b that is activated by Treg-cellexpressed integrin avb8? Controversy still exists as to whether TGF-b production by Treg cells is essential for their suppressive function, with different groups showing that Treg cells unable to produce TGF-b either are capable (Fahlé n et al., 2005; Kullberg et al., 2005) or incapable (Li et al., 2007; Nakamura et al., 2004) of suppressing T cells in transfer colitis models. Importantly, however, in a model of colitis where it was found that TGF-b1-deficient Treg cells were capable of suppressing inflammation to the same extent as control Treg cells, use of a TGF-b blocking antibody completely abrogated Treg-cell-mediated suppression, showing that TGF-b from non-Treg cell sources is capable of promoting suppression of inflammatory T cells (Fahlé n et al., 2005) . T cells that cannot express TGF-b1 can still be suppressed by Treg cells in colitis models, suggesting that T-cell-derived TGF-b is redundant for Treg cell function (Li et al., 2007) . However, when both T cells and Treg cells cannot make TGF-b, Treg cells show poor suppressive function (Li et al., 2007) . Thus, these data suggest that a combination of T-cell-and Treg-cell-produced TGF-b are important in mediating suppression by Treg cells. Given that many different hematopoietic and non-hematopoietic cells produce latent TGF-b and that high levels of latent TGF-b are found throughout the body, we propose that there will be some redundancy in the cell type producing functionally important latent complex for Treg-cell-mediated suppression. However, our data show that integrin avb8-mediated activation of latent TGF-b by Treg cells is absolutely required for the Treg-cell-mediated suppression of inflammatory T cell responses.
Another key observation from our study is that, although expression of integrin avb8 by Treg cells is essential for Tregcell-mediated suppression of T cells during ongoing inflammation, this pathway is not essential for Treg-cell-mediated suppression of self-harmful T cells during homeostasis. Mutations in foxp3 that result in lack of Treg cells result in lethal autoimmune disease in both mice and humans. However, lack of integrin avb8 specifically on Treg cells does not result in any overt inflammatory phenotype, strongly indicating that alternative mechanisms contribute to Treg-cell-mediated control of T cell homeostasis. Such mechanisms probably include IL-10-mediated suppression of T cells, given that lack of IL-10 production by Foxp3 + Treg cells in mice results in spontaneous inflammation at mucosal surfaces (Rubtsov et al., 2008) . Additionally, in agreement with recent work (Edwards et al., 2014) , Treg-cell-expressed integrin avb8 appears dispensable for inhibition of the initial development of inflammation in models of colitis ( We have discovered that integrin avb8 expression is upregulated on activated/eTreg cells, specifically on a KLRG1 + subset that have been shown to represent a terminally differentiated subset of eTreg cells (Feuerer et al., 2010) . This finding fits well with a specific role for Treg-cell-expressed integrin avb8 in suppressing T cells during active inflammation, when T cell and Treg cell activation will be prevalent. Indeed, we find that the KLRG1 + Treg cell subset is significantly expanded during inflammation. Our work therefore highlights the importance of understanding contextspecific pathways by which Treg cells promote suppression in order to better therapeutically target these cells; for example, to promote immune suppression during active disease. Finally, akin to observations in mice, we find that human Treg cells are specialized to express high levels of integrin avb8 and that this expression is enriched on the eTreg cell population. Thus, it appears that the expression profile of integrin avb8 translates directly from mouse studies, indicating that this pathway might be a useful therapeutic target in manipulation of human Treg cell suppressive function. Adoptive transfer of human Treg cells is currently in clinical trials for suppression of inflammation in type I diabetes and transplantation (Tang and Bluestone, 2013) , so identification of pathways that can be targeted to upregulate the suppressive capacity of these cells are likely to be extremely beneficial.
In conclusion, we have identified that both mouse and human Foxp3 + Treg cells express high levels of the integrin avb8, which is directly responsible for their ability to activate latent TGF-b, and lack of this pathway results in a failure of Treg cells to suppress T-cell-mediated inflammation. These data not only highlight a novel mechanism by which Treg cells mediate suppression via TGF-b, but also highlight potential specific treatments, via the manipulation of integrin avb8, to modulate Treg cell function to promote suppression of inflammation.
EXPERIMENTAL PROCEDURES Animals
Mice lacking T-cell-or Treg-cell-specific expression of integrin b8 were produced via crossing a conditional floxed allele of b8 integrin with Cd4-Cre (Travis et al., 2007) 
Treg Cell Activation
Treg cells were incubated overnight in 1 mg/ml of anti-CD3 and anti-CD28 antibody, and 5 ng/ml rhIL-2 or as described previously (Edwards et al., 2013) .
TGF-b Activation Assay
T cell subsets were incubated overnight with a TGF-b reporter cell line (Abe et al., 1994) and luciferase activity detected via the Luciferase Assay System (Promega). TGF-b activity was determined as previously described (Worthington et al., 2011b) . mix. Mice were monitored weekly for wasting disease. At 6-8 weeks after initial T cell transfer, 5 3 10 6 LILP cells were stimulated with anti-CD3 and anti-CD28 antibody (1 mg/ml) and supernatants were examined via ELISA or stimulated overnight with cell stimulation cocktail (eBioscience) and examined for cell populations and intracellular cytokines via flow cytometry.
T Cell Transfer Colitis
Histological Assessment of Inflammation
Tissues were fixed in 4% neutral buffered formalin and lungs were perfused before 5 mm paraffin-embedded sections were cut and stained with hematoxylin and eosin. Colitic inflammation was scored in a blinded fashion using a 0-3 scoring system based on the following five criteria: colon length, crypt hyperplasia and goblet cell depletion, lamina propria leukocyte infiltration, area affected, and severe break down of tissue architecture.
DSS Colitis Model
Mice received 1% DSS in drinking water and were monitored daily for weight loss before sacrifice at day 9 after treatment, before tissue samples were taken for histology and LILP cells were isolated (see Supplemental Experimental Procedures) and stained via flow cytometry.
DTH Model
Mice were immunized by s.c. injection of 300 mg Ova (Grade VI, Sigma-Aldrich) in 200 ml PBS/CFA emulsion (Sigma-Aldrich) and challenged 2 weeks later by s.c. injection of 50 mg Ova in 20 ml PBS into the right ear pinna while 20 ml PBS alone was injected into the left. Ear thickness was measured in a blinded fashion prior to and 48 hr after challenge with a caliper micrometer. Ears were split and digested dermis side down in 0.8% Trypsin at 37 C for 30 min before digestion to single-cell suspension in 0.5 Wunch units/ml Liberase TM (Roche) at 37 C for 1 hr. Ear draining lymph nodes were isolated, and single-cell suspensions were re-stimulated and examined via flow cytometry as previously described.
Statistical Analysis
Results are expressed as mean ± SEM. Where statistics are quoted, two experimental groups were compared via the Student's t test for non-parametric data. Three or more groups were compared with ANOVA, with Tuckey's post-test. p < 0.05 was considered statistically significant; *p < 0.05, **p < 0.01, ***p < 0.005. 
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